Annual Report — Form 10-K — SEA’34
Filing Table of Contents
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.55M
2: EX-10.04(A) Material Contract HTML 68K
3: EX-10.04(B) Material Contract HTML 59K
4: EX-21.1 Subsidiaries List HTML 30K
5: EX-23.1 Consent of Expert or Counsel HTML 30K
9: EX-97 Clawback Policy re: Recovery of Erroneously HTML 57K
Awarded Compensation
6: EX-31.1 Certification -- §302 - SOA'02 HTML 34K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 34K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 32K
11: R1 Cover HTML 103K
12: R2 Consolidated Balance Sheets HTML 155K
13: R3 Consolidated Balance Sheets (Parenthetical) HTML 50K
14: R4 Consolidated Statements of Operations HTML 133K
15: R5 Consolidated Statements of Comprehensive Loss HTML 60K
16: R6 Consolidated Statements of Changes in HTML 92K
Shareholders' Equity
17: R7 Consolidated Statements of Cash Flows HTML 146K
18: R8 Pay vs Performance Disclosure HTML 42K
19: R9 Insider Trading Arrangements HTML 35K
20: R10 Organization, Basis of Presentation and Liquidity HTML 66K
21: R11 Significant Accounting Policies HTML 108K
22: R12 Revenue HTML 103K
23: R13 Marketable Debt Securities HTML 70K
24: R14 Marketable Equity Securities HTML 49K
25: R15 Property and Equipment, Net HTML 50K
26: R16 Goodwill and Intangible Assets, Net HTML 63K
27: R17 Accounts Payable and Accrued Liabilities HTML 43K
28: R18 Fair Value Measurements HTML 105K
29: R19 Related Party Transactions HTML 36K
30: R20 Shareholders? Equity HTML 47K
31: R21 Stock-Based Awards HTML 134K
32: R22 Income Taxes HTML 145K
33: R23 Commitments and Contingencies HTML 182K
34: R24 Employee Benefit Plan HTML 32K
35: R25 Segment Information HTML 36K
36: R26 Enterprise-Wide Disclosures HTML 66K
37: R27 Selected Quarterly Financial Information HTML 93K
38: R28 Subsequent Events HTML 35K
39: R29 Significant Accounting Policies (Policies) HTML 164K
40: R30 Organization, Basis of Presentation and Liquidity HTML 41K
(Tables)
41: R31 Significant Accounting Policies (Tables) HTML 39K
42: R32 Revenue (Tables) HTML 102K
43: R33 Marketable Debt Securities (Tables) HTML 74K
44: R34 Marketable Equity Securities (Tables) HTML 43K
45: R35 Property and Equipment, Net (Tables) HTML 47K
46: R36 Goodwill and Intangible Assets, Net (Tables) HTML 62K
47: R37 Accounts Payable and Accrued Liabilities (Tables) HTML 43K
48: R38 Fair Value Measurements (Tables) HTML 99K
49: R39 Stock-Based Awards (Tables) HTML 140K
50: R40 Income Taxes (Tables) HTML 130K
51: R41 Commitments and Contingencies (Tables) HTML 131K
52: R42 Enterprise-Wide Disclosures (Tables) HTML 67K
53: R43 Selected Quarterly Financial Information (Tables) HTML 90K
54: R44 Organization, Basis of Presentation and Liquidity HTML 54K
- Additional Information (Details)
55: R45 Schedule of Lineage?s Ownership of Outstanding HTML 41K
Shares of its Subsidiaries (Details)
56: R46 Schedule of Lineage's Ownership of Outstanding HTML 37K
Shares of its Subsidiaries (Details)
(Parenthetical)
57: R47 Significant Accounting Policies - Schedule of HTML 36K
Anti-dilutive Securities Excluded from Computation
of Earnings Per Share (Details)
58: R48 Significant Accounting Policies - Additional HTML 139K
Information (Details)
59: R49 Revenue - Schedule of Disaggregated Revenues HTML 53K
(Details)
60: R50 Revenue - Schedule of Disaggregated Revenues HTML 43K
(Parenthetical) (Details)
61: R51 Revenue - Schedule of Contract with Customer HTML 34K
Contract Liability and Receivable (Details)
62: R52 Revenue - Schedule of Contract with Customer HTML 30K
Contract Liability and Receivable (Parenthetical)
(Details)
63: R53 Revenue - Schedule of Collaboration Agreements HTML 61K
(Details)
64: R54 Revenue - Schedule of Collaboration Agreements HTML 39K
(Details) (Paranthetical)
65: R55 Revenue - Additional Information (Details) HTML 46K
66: R56 Marketable Debt Securities - Additional HTML 34K
Information (Details)
67: R57 Marketable Debt Securities - Summary of Available HTML 43K
for Sale Debt Securities (Details)
68: R58 Marketable Debt Securities - Schedule of Amortized HTML 40K
cost And Estimated fair Value (Details)
69: R59 Marketable Equity Securities - Additional HTML 46K
Information (Details)
70: R60 Marketable Equity Securities - Schedule Of HTML 36K
Marketable Equity Securities (Details)
71: R61 Property and Equipment, Net - Schedule of Property HTML 47K
and Equipment, Net (Details)
72: R62 Property and Equipment, Net - Additional HTML 34K
Information (Details)
73: R63 Goodwill and Intangible Assets, Net - Schedule of HTML 57K
Goodwill and Intangible Assets Net (Details)
74: R64 Goodwill and Intangible Assets, Net - Schedule of HTML 43K
Goodwill and Intangible Assets Net (Details)
(Parenthetical)
75: R65 Goodwill and Intangible Assets, Net - Additional HTML 38K
Information (Details)
76: R66 Accounts Payable and Accrued Liabilities - HTML 39K
Schedule of Accounts Payable and Accrued
Liabilities (Details)
77: R67 Fair Value Measurements - Schedule of Fair Value HTML 64K
of Assets and Liabilities Valued on Recurring
Basis (Details)
78: R68 Related Party Transactions - Additional HTML 34K
Information (Details)
79: R69 Shareholders' Equity - Additional Information HTML 79K
(Details)
80: R70 Stock-Based Awards - Schedule of Share-based HTML 111K
Compensation Activity (Details)
81: R71 Stock-Based Awards - Schedule of Share-based HTML 41K
Compensation Activity (Details) (Parenthetical)
82: R72 Stock-Based Awards - Schedule of Weighted Average HTML 47K
Assumptions to Calculate Fair Value of Stock
Options (Details)
83: R73 Stock-Based Awards - Schedule of Stock Based HTML 37K
Compensation Expense (Details)
84: R74 Stock-Based Awards - Additional Information HTML 84K
(Details)
85: R75 Income Taxes - Schedule of Income before Income HTML 39K
Tax, Domestic and Foreign (Details)
86: R76 Income Taxes - Schedule of Income Tax Rate HTML 48K
Reconciliation (Details)
87: R77 Income Taxes - Schedule of Components of Deferred HTML 62K
Tax Assets and Liabilities (Details)
88: R78 Income Taxes - Schedule of Unrecognized Tax HTML 35K
Benefits Roll Forward (Details)
89: R79 Income Taxes - Additional Information (Details) HTML 83K
90: R80 Commitments and Contingencies - Schedule of HTML 41K
Supplemental Cash Flow Information Related to
Leases (Details)
91: R81 Commitments and Contingencies - Schedule of HTML 69K
Supplemental Balance Sheet Information Related to
Leases (Details)
92: R82 Commitments and Contingencies - Schedule of Future HTML 65K
Minimum Lease Commitments (Details)
93: R83 Commitments and Contingencies - Additional HTML 181K
Information (Details)
94: R84 Employee Benefit Plan - Additional Information HTML 33K
(Details)
95: R85 Segment Information - Additional Information HTML 31K
(Details)
96: R86 Enterprise-Wide Disclosures - Schedule of HTML 37K
Geographic Area Information (Details)
97: R87 Enterprise-Wide Disclosures - Schedule of Revenues HTML 43K
Disaggregated by Source (Details)
98: R88 Selected Quarterly Financial Information - HTML 70K
Schedule of Selected Quarterly Financial
Information (Details)
99: R89 Subsequent Events - Additional Information HTML 47K
(Details)
101: XML IDEA XML File -- Filing Summary XML 196K
104: XML XBRL Instance -- lctx-20231231_htm XML 2.73M
100: EXCEL IDEA Workbook of Financial Report Info XLSX 160K
10: EX-101.SCH XBRL Taxonomy Extension Schema With Embedded XSD 4.46M
Linkbases Document -- lctx-20231231
102: JSON XBRL Instance as JSON Data -- MetaLinks 634± 921K
103: ZIP XBRL Zipped Folder -- 0000950170-24-027988-xbrl Zip 1.21M
‘EXCEL’ — IDEA Workbook of Financial Report Info
This is an IDEA Workbook.
2 Subsequent Filings that Reference this Filing
28 Previous Filings that this Filing References
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent
2/06/24 Lineage Cell Therapeutics, Inc. 8-K:1,8,9 2/06/24 13:375K M2 Compliance LLC/FA
7/27/23 Lineage Cell Therapeutics, Inc. DEF 14A 7/27/23 1:5.3M M2 Compliance LLC/FA
3/09/23 Lineage Cell Therapeutics, Inc. 10-K 12/31/22 105:11M M2 Compliance LLC/FA
11/10/22 Lineage Cell Therapeutics, Inc. 10-Q 9/30/22 86:8.4M M2 Compliance LLC/FA
8/11/22 Lineage Cell Therapeutics, Inc. 10-Q 6/30/22 82:7.9M M2 Compliance LLC/FA
3/10/22 Lineage Cell Therapeutics, Inc. 10-K 12/31/21 106:11M M2 Compliance LLC/FA
9/28/21 Lineage Cell Therapeutics, Inc. S-8 9/28/21 6:275K M2 Compliance LLC/FA
9/15/21 Lineage Cell Therapeutics, Inc. 8-K:5,9 9/13/21 11:420K M2 Compliance LLC/FA
8/12/21 Lineage Cell Therapeutics, Inc. 10-Q 6/30/21 76:7.5M M2 Compliance LLC/FA
3/11/21 Lineage Cell Therapeutics, Inc. 10-K 12/31/20 100:10M M2 Compliance LLC/FA
8/06/20 Lineage Cell Therapeutics, Inc. 10-Q 6/30/20 83:8.9M M2 Compliance LLC/FA
3/12/20 Lineage Cell Therapeutics, Inc. 10-K 12/31/19 101:8.9M M2 Compliance LLC/FA
11/12/19 Lineage Cell Therapeutics, Inc. 10-Q 9/30/19 83:6.4M M2 Compliance LLC/FA
8/12/19 Lineage Cell Therapeutics, Inc. 8-K:5,8,9 8/09/19 3:225K M2 Compliance LLC/FA
8/08/19 Lineage Cell Therapeutics, Inc. S-8 8/08/19 4:128K M2 Compliance LLC/FA
3/14/19 Lineage Cell Therapeutics, Inc. 10-K 12/31/18 102:9.3M M2 Compliance LLC/FA
11/08/18 Lineage Cell Therapeutics, Inc. 8-K:1,8,9 11/07/18 3:820K M2 Compliance LLC/FA
5/10/18 Lineage Cell Therapeutics, Inc. 10-Q 3/31/18 67:3.5M M2 Compliance LLC/FA
3/15/18 Lineage Cell Therapeutics, Inc. 10-K 12/31/17 92:10M M2 Compliance LLC/FA
8/09/17 Lineage Cell Therapeutics, Inc. 10-Q 6/30/17 58:5.9M Broadridge Fin’l So… Inc
7/07/17 Lineage Cell Therapeutics, Inc. S-8 7/07/17 4:124K M2 Compliance LLC/FA
7/15/15 Lineage Cell Therapeutics, Inc. S-8 7/15/15 5:250K Broadridge Fin’l So… Inc
1/13/15 Asterias Biotherapeutics, Inc. 10-Q/A 9/30/14 3:1.2M Broadridge Fin’l So… Inc
11/12/13 Asterias Biotherapeutics, Inc. 10-Q 9/30/13 49:5.2M Broadridge Fin’l So… Inc
11/12/13 Lineage Cell Therapeutics, Inc. 10-Q 9/30/13 58:6.4M Broadridge Fin’l So… Inc
8/13/13 Asterias Biotherapeutics, Inc. S-1/A¶ 14:2.9M Broadridge Fin’l So… Inc
3/23/09 Lineage Cell Therapeutics, Inc. 10-K 12/31/08 8:2M
1/09/08 Lineage Cell Therapeutics, Inc. 8-K:1,7,9 1/03/08 3:615K Broadridge Fin’l So… Inc
|
↑Top
Filing Submission 0000950170-24-027988 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help —
Sun., May 12, 1:03:07.3am ET 
